Advertisement

Genetic Predisposition and Hereditary Syndromes

  • Ana Carolina Ribeiro Chaves de Gouvea
  • Andrea Clemente Baptista Silva
  • Carolina Ribeiro Victor
  • Elizabeth Zambrano Mendoza
  • Mirella Nardo
  • Rodrigo Santa Cruz Guindalini
Chapter

Abstract

Hereditary diffuse gastric cancer (GC) is a syndrome with autosomal dominant inheritance related to germline mutations in the CDH1 gene (CDH1-calcium-dependent adhesion protein) leading to changes in the expression of the E-cadherin protein. This syndrome has a high cumulative lifetime risk of developing diffuse gastric and lobular breast carcinomas. Patients who meet the clinical criteria for the syndrome and their relatives should be tested. When a genetic test is positive for a pathogenic variant, the patient should be strongly advised to consider prophylactic gastrectomy. Total gastrectomy for these patients dramatically reduces their risk of GC development. For mutation carriers for whom surgery is not an option, annual standardized endoscopic surveillance is recommended, but it is not as effective as prophylactic gastrectomy. Breast cancer screening is recommended starting at 30 years of age with annual breast magnetic resonance imaging. Prophylactic mastectomy is not routinely recommended, and surgical management should be discussed on a case-by-case basis depending on family history.

Keywords

Hereditary diffuse gastric cancer CDH1 Mutation Genetic counseling E-cadherin Surveillance 

References

  1. 1.
    Ferlay J, Soerjomataram I, & Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet]. International Agency for Research on Cancer, Lyon, 2014.Google Scholar
  2. 2.
    Van der Post RS, Vogelaar IP, Carmeorp F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52:361–74.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Takeichi M, Hirano S, Matsuyoshi N, Fujimori T. Cytoplasmic control of cadherin-mediated cell-cell adhesion. Cold Spring Harb Symp Quant Biol. 1992;57:327–34.CrossRefPubMedGoogle Scholar
  5. 5.
    Corso G, Carvalho J, Marrelli D, Vindigni C, Carvalho B, Seruca R, Roviello F, Oliveira C. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol. 2013;31(7):868–75.  https://doi.org/10.1200/JCO.2012.44.4612. Epub 2013 Jan 22.CrossRefPubMedGoogle Scholar
  6. 6.
    Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer. 2010;13:1–10.CrossRefPubMedGoogle Scholar
  7. 7.
    Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297:2360–72.CrossRefPubMedGoogle Scholar
  8. 8.
    Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, Lewis FR, Huntsman DG, Pharoah PD, Jankowski JA, MacLeod P, Vogelsang H, Keller G, Park KG, Richards FM, Maher ER, Gayther SA, Oliveira C, Grehan N, Wight D, Seruca R, Roviello F, Ponder BA, Jackson CE. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36:873–80.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Brito LA, Yamamoto GL, Melo S, Malcher C, Ferreira SG, Figueiredo J, Alvizi L, Kobayashi GS, Naslavsky MS, Alonso N, Feliz TM, Zatz M, Seruca R, Passos Bueno MR. Rare variants in the epithelial cadherin gene underlying the genetic etiology of nonsyndromic cleft lip with or without cleft palate. Hum Mutat. 2015;36(11):1029–33.  https://doi.org/10.1002/humu.22827.CrossRefPubMedGoogle Scholar
  10. 10.
    Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C, International Gastric Cancer Linkage Consortium. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47:436–44.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mouret-Fourme E, Noguès C, Di Maria M, Tlemsani C, Warcoin M, Grandjouan S, Malka D, Caron O, Blayau M. Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with a CDH1 germline mutation. J Med Genet. 2015;52(8):563–5.Google Scholar
  12. 12.
    Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol. 2006;4:262–75.CrossRefPubMedGoogle Scholar
  13. 13.
    Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G, Almeida Santos T, Claro I, Carvalho J, Nielsen C, Padilla S, Lum A, Talhouk A, Baker-Lange K, Richardson S, Lewis I, Lindor NM, Pennell E, MacMillan A, Fernandez B, Keller G, Lynch H, Shah SP, Guilford P, Gallinger S, Corso G, Roviello F, Caldas C, Oliveria C, Pharoah PDP, Huntsman DG. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1:23.CrossRefPubMedGoogle Scholar
  14. 14.
    Oliveira C, Senz J, Kaurah P, et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet. 2009;18:1545–55.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Oliveira C, Seruca R, Hoogerbrugge N, et al. Clinical utility gene card for: hereditary diffuse gastric cancer (HDGC). Eur J Hum Genet. 2013;21(8):e1–5 [Epub ahead of print].Google Scholar
  16. 16.
    Humar B, Guilford P. Hereditary diffuse gastric cancer: a manifestation of lost cell polarity. Cancer Sci. 2009;100:1151–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Majewski IJ, Kluijt I, Cats A, et al. An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol. 2013;229(4):621–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41:508–17.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Moll R, Mitze M, Frixen UH, Birchmeier W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 1993;143(6):1731–42.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Brem RF, Ioffe M, Rapelyea JA, Yost KG, Weigert JM, Bertrand ML, Stern LH. Invasive lobular carcinoma: detection with mammography, sonography, MRI, and breast-specific gamma imaging. AJR Am J Roentgenol. 2009;192(2):379–83.CrossRefPubMedGoogle Scholar
  21. 21.
    Oliveira TM, Elias J Jr, Melo AF, Teixeira SR, Filho SC, Gonçalves LM, Faria FM, Tiezzi DG, Andrade JM, Muglia V. Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods. Insights Imaging. 2014;5(2):183–94.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, Kato Y. Incidence of lymph node metastasis from early gastric cancer: estimation with a 99 large number of cases at two large centers. Gastric Cancer. 2000;3:219–25.CrossRefPubMedGoogle Scholar
  23. 23.
    Roviello F, Rossi S, Marrelli D, Pedrazzani C, Corso G, Vindigni C, Morgagni P, Saragoni L, de Manzoni G, Tomezzoli A. Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study. J Surg Oncol. 2006;94:275–80; discussion 4.CrossRefPubMedGoogle Scholar
  24. 24.
    Muir J, Aronson M, Esplen MJ, Pollett A, Swallow CJ. Prophylactic Total gastrectomy: a prospective cohort study of long-term impact on quality of life. J Gastrointest Surg. 2016;20(12):1950–8. Epub 2016 Oct 17.CrossRefPubMedGoogle Scholar
  25. 25.
    Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ana Carolina Ribeiro Chaves de Gouvea
    • 1
  • Andrea Clemente Baptista Silva
    • 2
  • Carolina Ribeiro Victor
    • 2
  • Elizabeth Zambrano Mendoza
    • 2
  • Mirella Nardo
    • 2
  • Rodrigo Santa Cruz Guindalini
    • 3
    • 4
  1. 1.Centro de Oncologia Hospital Alemao Oswaldo CruzSão PauloBrazil
  2. 2.Faculdade de Medicina da Universidade de São Paulo/Instituto do Câncer do Estado de São PauloSão PauloBrazil
  3. 3.Centro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São PauloSão PauloBrazil
  4. 4.CLION, CAM GroupSalvadorBrazil

Personalised recommendations